Featuring an interview with Dr Bijal Shah, including the following topics:

• Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00)
• Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51)
• Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56)
• Extramedullary ALL, including in the CNS (13:32)
• Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34)
• Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37)
• Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48)
• Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16)
• Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics:

• Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00)
• Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29)
• Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27)
• Key clinical trial data with surovatamig; implications for practice (32:38)
• Key clinical trial data with MK-1045; implications for practice (39:02)
• Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36)

CME information and select publications

Featuring an interview with Prof Constantine Tam, including the following topics:

• Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00)
• Considerations for the administration of first-line venetoclax-based regimens (3:24)
• Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01)
• Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38)
• Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07)
• Up-front treatment selection for patients with del(17p) CLL (24:01)
• Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43)
• Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20)
• Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00)
• Perspectives on future roles of novel therapies and treatment strategies (43:11)

CME information and select publications